BR112015009871A2 - composições farmacêuticas compreendendo hidromorfona e naloxona - Google Patents
composições farmacêuticas compreendendo hidromorfona e naloxonaInfo
- Publication number
- BR112015009871A2 BR112015009871A2 BR112015009871A BR112015009871A BR112015009871A2 BR 112015009871 A2 BR112015009871 A2 BR 112015009871A2 BR 112015009871 A BR112015009871 A BR 112015009871A BR 112015009871 A BR112015009871 A BR 112015009871A BR 112015009871 A2 BR112015009871 A2 BR 112015009871A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydromorphone
- naloxone
- dosage form
- pharmaceutical compositions
- granule
- Prior art date
Links
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 title abstract 4
- 229960001410 hydromorphone Drugs 0.000 title abstract 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title abstract 4
- 229960004127 naloxone Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 abstract 1
- 229940001584 sodium metabisulfite Drugs 0.000 abstract 1
- 235000010262 sodium metabisulphite Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
resumo “composições farmacêuticas compreendendo hidromorfona e naloxona” a presente invenção apresenta uma forma de dosagem farmacêutica de liberação prolongada compreendendo uma pluralidade de microesferas revestidas, que compreendem, cada, um grânulo, uma primeira camada aplicada como revestimento sobre o grânulo, compreendendo hidromorfona, naloxona, um composto antioxidante e um composto quelante; e uma segunda camada aplicada como revestimento sobre a primeira camada compreendendo um agente de liberação prolongada. a forma de dosagem tem propriedades de estabilidade e dissolução aprimoradas. também é apresentado o uso de uma combinação de um antioxidante, como metabissulfito de sódio, e um agente quelante, como edta, para melhorar as propriedades de estabilidade e/ou dissolução de uma forma de dosagem de liberação prolongada compreendendo hidromorfona e naloxona.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261796390P | 2012-11-09 | 2012-11-09 | |
CA2795324A CA2795324C (en) | 2012-11-09 | 2012-11-09 | Pharmaceutical compositions comprising hydromorphone and naloxone |
PCT/CA2013/000932 WO2014071499A1 (en) | 2012-11-09 | 2013-11-06 | Pharmaceutical compositions comprising hydromorphone and naloxone |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015009871A2 true BR112015009871A2 (pt) | 2017-07-11 |
Family
ID=50679506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015009871A BR112015009871A2 (pt) | 2012-11-09 | 2013-11-06 | composições farmacêuticas compreendendo hidromorfona e naloxona |
Country Status (13)
Country | Link |
---|---|
US (2) | US20150283091A1 (pt) |
JP (2) | JP6359022B2 (pt) |
KR (1) | KR101774676B1 (pt) |
CN (1) | CN104902880B (pt) |
AU (1) | AU2013344281B2 (pt) |
BR (1) | BR112015009871A2 (pt) |
CA (2) | CA2795324C (pt) |
HK (1) | HK1210042A1 (pt) |
MX (1) | MX363142B (pt) |
PH (1) | PH12015501015B1 (pt) |
SA (1) | SA515360408B1 (pt) |
SG (1) | SG11201502752VA (pt) |
WO (1) | WO2014071499A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
NZ603170A (en) | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
AU2014350135B2 (en) | 2013-11-13 | 2017-08-31 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
CA2847781C (en) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reducing drug liking in a subject |
US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
EP3177146A4 (en) | 2014-07-08 | 2018-01-03 | Insys Pharma, Inc. | Sublingual naloxone spray |
US10617686B2 (en) | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
AU2017312811B2 (en) * | 2016-08-17 | 2023-03-16 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
CN108186599A (zh) * | 2018-03-05 | 2018-06-22 | 上海祺宇生物科技有限公司 | 一种高隔氧率的羟丙甲基纤维素空心胶囊及其制备方法 |
AU2020245535B2 (en) * | 2019-03-26 | 2022-06-30 | Pocket Naloxone Corp. | Devices and methods for delivering pharmaceutical compositions |
EP3946547A4 (en) | 2019-03-26 | 2023-01-18 | Pocket Naloxone Corp. | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS |
US20240043447A1 (en) * | 2020-11-13 | 2024-02-08 | Ferrer Internacional, S.A. | Synthesis of hydromorphone base |
US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
WO1998035679A1 (de) * | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilisierung von naloxonhydrochlorid |
EP0913152B1 (de) * | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum |
TWI223598B (en) * | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
US6071952A (en) * | 1998-12-02 | 2000-06-06 | Mylan Pharmaceuticals, Inc. | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
WO2003077867A2 (en) * | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
AU2003220551A1 (en) * | 2002-03-26 | 2003-10-13 | Euro-Celtique S.A. | Sustained-release gel coated compositions |
JP2006076971A (ja) * | 2004-09-13 | 2006-03-23 | Basf Ag | 口腔内崩壊錠 |
GEP20105052B (en) * | 2005-01-28 | 2010-07-26 | Euro Celtique Sa | Alcohol resistant dosage forms |
EP1888030A1 (en) * | 2005-05-25 | 2008-02-20 | Janssen Pharmaceutica N.V. | Pediatric formulation of topiramate |
PT2057984E (pt) * | 2007-11-09 | 2010-03-10 | Acino Pharma Ag | Comprimidos retard com hidromorfona |
EP3342427A1 (en) * | 2008-09-16 | 2018-07-04 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
MX2012000369A (es) * | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion. |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
US8597681B2 (en) * | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9700508B2 (en) * | 2010-05-10 | 2017-07-11 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
NZ603170A (en) * | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
AR088250A1 (es) * | 2011-10-06 | 2014-05-21 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
-
2012
- 2012-11-09 CA CA2795324A patent/CA2795324C/en active Active
- 2012-11-09 CA CA2881144A patent/CA2881144A1/en not_active Abandoned
-
2013
- 2013-11-06 SG SG11201502752VA patent/SG11201502752VA/en unknown
- 2013-11-06 US US14/441,814 patent/US20150283091A1/en not_active Abandoned
- 2013-11-06 AU AU2013344281A patent/AU2013344281B2/en active Active
- 2013-11-06 WO PCT/CA2013/000932 patent/WO2014071499A1/en active Application Filing
- 2013-11-06 CN CN201380058652.4A patent/CN104902880B/zh active Active
- 2013-11-06 BR BR112015009871A patent/BR112015009871A2/pt not_active Application Discontinuation
- 2013-11-06 MX MX2015005534A patent/MX363142B/es unknown
- 2013-11-06 KR KR1020157014868A patent/KR101774676B1/ko active IP Right Grant
- 2013-11-06 JP JP2015540971A patent/JP6359022B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-06 PH PH12015501015A patent/PH12015501015B1/en unknown
- 2015-05-09 SA SA515360408A patent/SA515360408B1/ar unknown
- 2015-11-05 HK HK15110909.2A patent/HK1210042A1/xx not_active IP Right Cessation
-
2017
- 2017-03-21 JP JP2017054318A patent/JP2017149725A/ja active Pending
-
2018
- 2018-10-19 US US16/165,915 patent/US20190224130A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SA515360408B1 (ar) | 2017-04-03 |
CA2795324A1 (en) | 2014-05-09 |
WO2014071499A1 (en) | 2014-05-15 |
KR101774676B1 (ko) | 2017-09-04 |
JP2017149725A (ja) | 2017-08-31 |
SG11201502752VA (en) | 2015-05-28 |
CN104902880B (zh) | 2017-08-11 |
KR20150085825A (ko) | 2015-07-24 |
MX363142B (es) | 2019-03-12 |
CA2881144A1 (en) | 2014-05-09 |
PH12015501015A1 (en) | 2015-07-27 |
AU2013344281A1 (en) | 2015-05-07 |
US20150283091A1 (en) | 2015-10-08 |
US20190224130A1 (en) | 2019-07-25 |
AU2013344281B2 (en) | 2016-07-28 |
JP6359022B2 (ja) | 2018-07-18 |
PH12015501015B1 (en) | 2015-07-27 |
CA2795324C (en) | 2015-07-14 |
JP2015536956A (ja) | 2015-12-24 |
CN104902880A (zh) | 2015-09-09 |
MX2015005534A (es) | 2016-06-02 |
HK1210042A1 (en) | 2016-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015009871A2 (pt) | composições farmacêuticas compreendendo hidromorfona e naloxona | |
PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
PH12016500170A1 (en) | Formulation of syk inhibitors | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
BR112017002214A2 (pt) | composto de fórmula (i), composição farmacêutica e usos de um composto | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
BR112016025910A8 (pt) | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos | |
BR112015028770A2 (pt) | composição de polipropileno duro adequada para pintura sem base | |
UY35298A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
CY1122113T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
NI201500115A (es) | Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
CR20120549A (es) | Composiciones farmacèuticas que comprenden hidromorfona y naloxona | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
BR112012022101A2 (pt) | agente para melhorar a deposição de óleo sobre os cabelos. | |
BR112012027303A2 (pt) | comprimido de desintegração oral contendo acarbose | |
AU2016204294A1 (en) | Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor | |
WO2014182789A3 (en) | Radiomitigating pharmaceutical formulations | |
PH12015502093A1 (en) | Antiemetic extended release solid dosage forms | |
CY1123933T1 (el) | Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης | |
GEP201706743B (en) | Oral formulation for the treatment of cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |